A Single Ascending Dose of HRS-4029 in Healthy Subjects
NCT06905314 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55
Last updated 2025-04-01
Summary
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.
Conditions
- Acute Ischemic Stroke
Interventions
- DRUG
-
HRS-4029
HRS-4029
- DRUG
-
Placebo
Sponsors & Collaborators
-
Beijing Suncadia Pharmaceuticals Co., Ltd
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-04-30
- Primary Completion
- 2025-10-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults
NCT05636306 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess PK, Safety and Tolerability Early in Healthy Subjects
NCT06388772 ·Status: COMPLETED ·Phase: PHASE1
-
SY007 in Patients With Acute Ischemic Stroke
NCT04891913 ·Status: SUSPENDED ·Phase: PHASE1
-
Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke
NCT04950790 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Efficacy Study in Acute Ischaemic Stroke
NCT00144014 ·Status: COMPLETED ·Phase: PHASE2
-
HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.
NCT07233070 ·Status: RECRUITING ·Phase: PHASE2
-
Suhexiang Pill for Acute Ischemic Stroke: A Registry Study
NCT05833932 ·Status: RECRUITING
-
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
NCT05515393 ·Status: UNKNOWN ·Phase: PHASE2
-
Y-3 for Injection in the Treatment of Acute Ischemic Stroke
NCT06517173 ·Status: RECRUITING ·Phase: PHASE3
-
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
NCT01273467 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of CN-105 in Subject With Acute Supratentorial Intracerebral Hemorrhage
NCT03711903 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
NCT07279493 ·Status: RECRUITING ·Phase: PHASE2
-
Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke
NCT02059785 ·Status: SUSPENDED ·Phase: PHASE2
-
Study Evaluating Single Ascending Doses Of ILS-920
NCT00827190 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
NCT07241520 ·Status: RECRUITING ·Phase: PHASE3
-
A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke
NCT07205328 ·Status: RECRUITING ·Phase: PHASE2
-
Ginsenoside-Rd for Acute Ischemic Stroke
NCT00591084 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
NCT00821821 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess PK, Safety and Tolerability in Healthy Subjects
NCT06380699 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects
NCT04111523 ·Status: COMPLETED ·Phase: PHASE1
-
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
NCT04290494 ·Status: COMPLETED
-
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
NCT00272909 ·Status: TERMINATED ·Phase: PHASE2
-
Endovascular Therapy for Acute Ischemic Stroke Trial
NCT02350283 ·Status: COMPLETED ·Phase: PHASE3
-
"The Effect of Trimetazidine on the Clinical Outcome of Acute Ischemic Stroke Patients"
NCT06656442 ·Status: COMPLETED ·Phase: PHASE3